{"id":51074,"date":"2022-11-21T14:02:17","date_gmt":"2022-11-21T13:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/"},"modified":"2022-11-21T14:02:17","modified_gmt":"2022-11-21T13:02:17","slug":"healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/","title":{"rendered":"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun"},"content":{"rendered":"
\n

\nThe acquisition will accelerate the launch of Healiva\u2019s personalised skin regeneration therapy, EpiDex\u00ae\n<\/p>\n

<\/a><\/p>\n

LUGANO, Switzerland–(BUSINESS WIRE)–#Burdenofwounds<\/a>—Healiva<\/a>\u00ae, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva\u2019s first cell therapy product, EpiDex\u00ae: an autologous epidermis derived from the patient\u2019s own hair cells. Financial details have not been disclosed.\n<\/p>\n

\n\u201cThis transaction will enable Healiva to accelerate the launch of EpiDex, which is projected for Q4 2023,\u201d said Priyanka Dutta-Passecker (MBA, PhD), Co-founder and CEO of Healiva. \u201cThis will allow us to deliver our clinically proven, surgery-free solution to patients with severe chronic wounds more promptly, shortening the path to market for EpiDex by approximately one year.\u201d\n<\/p>\n

\n\u201cTo produce EpiDex, progenitor keratinocyte cells obtained from a patient\u2019s hair are cultured in the presence of fibroblast feeder cells, generating small discs of autologous epidermis,\u201d explained Eric Rolland (PhD), Scientific Lead and Advisor at Healiva. \u201cThese discs are then applied onto the wound, where they promote the growth and healing of the skin.\u201d\n<\/p>\n

\n\u201cThe acquisition of a qualified fibroblast cell bank that meets the regulatory requirements for Advanced Therapy Medicinal Products (ATMPs) and has previously been approved for the commercial production of EpiDex is a key step in Healiva\u2019s product development,\u201d added Andreas Emmendoerffer (MD, PhD), Clinical Advisor at Healiva.\n<\/p>\n

\nEpiDex forms part of Healiva\u2019s broad wound care portfolio, which combines cell therapy, medical devices, and enzyme technology to cover the whole wound healing process. EpiDex solves an urgent need for new solutions to treat chronic venous leg ulcers and other chronic wounds, which affect 60 million patients worldwide. With an aging population, combined with the growing incidence of metabolic diseases, this burden is growing. Today, the standard treatment for chronic wounds requires multiple procedures, with surgery required in the most severe cases. EpiDex is as effective as surgery for severe chronic wounds, while being more cost-effective and significantly preferred by patients.\n<\/p>\n

\nEpiDex had previously been approved for the Swiss market. EpiDex will be launched initially in Switzerland, pending approval by Swissmedic, followed by Germany and other EMEA countries. Healiva intends to first seek reimbursement in Switzerland for EpiDex, followed by other European countries.\n<\/p>\n

\nAbout Healiva
\n
<\/b>Healiva<\/a> is a patient-centric biotech company delivering life-enhancing precision medicine for patients with chronic and acute ulcers. The company was founded in 2020 by Bioseutica BV and Priyanka Dutta-Passecker (PhD, MBA).\n<\/p>\n

\nTo learn more, visit www.healiva.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:
\n
Healiva SA
\n
Priyanka Dutta-Passecker
\n
Co-founder and CEO
\n
More information<\/a>\n<\/p>\n

\nMedia Contact:
\n
contact@healiva.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The acquisition will accelerate the launch of Healiva\u2019s personalised skin regeneration therapy, EpiDex\u00ae LUGANO, Switzerland–(BUSINESS WIRE)–#Burdenofwounds—Healiva\u00ae, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51074","6":"format-standard","7":"category-industry"},"yoast_head":"\nHealiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The acquisition will accelerate the launch of Healiva\u2019s personalised skin regeneration therapy, EpiDex\u00ae LUGANO, Switzerland–(BUSINESS WIRE)–#Burdenofwounds—Healiva\u00ae, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T13:02:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221121005016\/en\/1637839\/21\/Healiva_logopng.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun\",\"datePublished\":\"2022-11-21T13:02:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/\"},\"wordCount\":468,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005016\\\/en\\\/1637839\\\/21\\\/Healiva_logopng.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/\",\"name\":\"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005016\\\/en\\\/1637839\\\/21\\\/Healiva_logopng.jpg\",\"datePublished\":\"2022-11-21T13:02:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005016\\\/en\\\/1637839\\\/21\\\/Healiva_logopng.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005016\\\/en\\\/1637839\\\/21\\\/Healiva_logopng.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/","og_locale":"en_US","og_type":"article","og_title":"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun - Pharma Trend","og_description":"The acquisition will accelerate the launch of Healiva\u2019s personalised skin regeneration therapy, EpiDex\u00ae LUGANO, Switzerland–(BUSINESS WIRE)–#Burdenofwounds—Healiva\u00ae, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-21T13:02:17+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221121005016\/en\/1637839\/21\/Healiva_logopng.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun","datePublished":"2022-11-21T13:02:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/"},"wordCount":468,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221121005016\/en\/1637839\/21\/Healiva_logopng.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/","url":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/","name":"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221121005016\/en\/1637839\/21\/Healiva_logopng.jpg","datePublished":"2022-11-21T13:02:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221121005016\/en\/1637839\/21\/Healiva_logopng.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221121005016\/en\/1637839\/21\/Healiva_logopng.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51074"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51074\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}